hypersplenism: Overactive functioning of the spleen, resulting in excessive destruction of blood cells.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
186 |
4. Check minimum number of eventsNone |
186 |
5. Include endpointsNone |
186 |
6. Filter based on genotype QC (FinnGen only) |
158 |
Control definitions (FinnGen only)
- Control exclude
- D3_BLOODOTHER
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D73
- Name in latin
- Hypersplenismus
Similar endpoints
↥List of similar endpoints to
Hypersplenism
based on the number of shared cases.
Similar with more cases:
- Diseases of spleen
- Other diseases of blood and blood-forming organs, wide
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Any operation in hilmo
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1082 | 469 | 602 |
| Only index persons | 882 | 381 | 501 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.01 | 0.02 |
| Only index persons | 0.02 | 0.01 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 58.66 | 59.57 | 57.67 |
| Only index persons | 56.73 | 57.62 | 56.06 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 158 | 72 | 86 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.04 |
| Median age at first event (years) | 58.41 | 56.36 | 60.12 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 162
- Matched controls
- 1620
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D73.1
ICD-10 Finland
Hypersplenism
+∞
225.4
159
*
XW000
NOMESCO Finland
Bone marrow biopsy
36.7
82.6
56
23
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
11.1
52.0
77
122
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
76.4
32.6
36
6
R16.1
ICD-10 Finland
Splenomegaly, not elsewhere classified
382.7
32.0
31
*
D64.9
ICD-10 Finland
Anaemia, unspecified
8.2
32.0
53
91
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
6.2
30.5
95
300
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
11.8
28.6
32
33
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
7.1
24.5
44
81
A49.9
ICD-10 Finland
Bacterial infection, unspecified
6.1
22.5
48
104
C03CA01
ATC
furosemide; systemic
4.5
20.4
81
292
K74.6
ICD-10 Finland
Other and unspecified cirrhosis of liver
36.6
19.9
25
8
J01MA12
ATC
levofloxacin; systemic
4.7
19.2
60
179
R50.9
ICD-10 Finland
Fever, unspecified
4.8
18.7
56
161
JMA10
NOMESCO Finland
Transabdominal total splenectomy
106.9
18.0
19
*
I85.9
ICD-10 Finland
Oesophageal varices without bleeding
71.2
17.1
19
*
D70.89
ICD-10 Finland
Neutropenic splenomegaly
188.6
16.8
17
*
JN4BD
NOMESCO Finland
Extensive body CT
5.1
16.3
41
101
WW500
NOMESCO Finland
Blood transfusion
13.8
16.3
28
24
C03DA01
ATC
spironolactone; oral
4.9
16.0
43
112
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.0
15.8
111
569
ZX120
NOMESCO Finland
Intravenous
5.3
15.4
36
83
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
6.4
15.4
28
51
C83.80
ICD-10 Finland
B-cell lymphoma in marginal zone
+∞
14.8
14
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
6.1
13.8
26
49
JN4AD
NOMESCO Finland
Body CT examination
4.4
12.8
38
106
JN3BD
NOMESCO Finland
Extensive abdominal CT
4.6
12.1
33
86
TPH04
NOMESCO Finland
Cathetrisation of vein
3.4
11.6
57
224
D47.1
ICD-10 Finland
Chronic myeloproliferative disease
128.8
11.6
12
*
TPH07
NOMESCO Finland
Cathetrisation of artery
4.4
11.4
32
85
A05AA02
ATC
ursodeoxycholic acid; oral
27.3
11.4
15
6
WW200
NOMESCO Finland
Immunization
14.3
11.0
18
14
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
30.4
10.9
14
5
M04AA01
ATC
allopurinol; systemic
3.7
10.4
39
128
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.1
10.3
60
259
K70.3
ICD-10 Finland
Alcoholic cirrhosis of liver
28.0
10.0
13
5
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
3.7
9.9
37
121
JN3DE
NOMESCO Finland
Abdominal extensive ultrasoudn examination with blood flow measurements after transplantation
58.6
9.8
11
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.3
9.8
45
168
I85.0
ICD-10 Finland
Oesophageal varices with bleeding
+∞
9.5
9
*
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
16.9
9.2
14
9
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.7
9.1
32
100
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
4.6
9.1
23
56
JN3AD
NOMESCO Finland
Abdominal CT examination
3.5
9.0
36
122
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.7
8.9
78
413
127
Kela drug reimbursment
Transplant complication
21.4
8.6
12
6
L04AD02
ATC
tacrolimus; systemic
94.8
8.5
9
*
D80.1
ICD-10 Finland
Nonfamilial hypogammaglobulinaemia
94.8
8.5
9
*
9689/3-C42.2
ICD-O-3
Splenic marginal zone B-cell lymphoma of spleen
+∞
8.4
8
*
K92.1
ICD-10 Finland
Melaena
5.2
8.3
18
38
C07AB07
ATC
bisoprolol; oral
2.6
8.2
94
560
JDW98
NOMESCO Finland
Other transluminal endoscopic operation on stomach or duodenum
23.4
8.1
11
5
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
4.5
8.1
21
52
R18
ICD-10 Finland
Ascites
14.0
8.0
13
10
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
4.8
7.9
19
44
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
16.1
7.8
12
8
JMA11
NOMESCO Finland
Laparoscopic total splenectomy
47.3
7.8
9
*
JJ1LE
NOMESCO Finland
Ultrasound elastography of liver
26.4
7.7
10
*
UJF30
NOMESCO Finland
Ileoscopy through colon
3.7
7.7
27
84
JN6AD
NOMESCO Finland
CT of torso and neck
14.3
7.5
12
9
UJF32
NOMESCO Finland
Coloscopy
2.7
7.5
55
262
XW4XT
NOMESCO Finland
Biopsy of other inner organ with radiological guidance guidance
83.8
7.5
8
*
I81
ICD-10 Finland
Portal vein thrombosis
83.8
7.5
8
*
JKE98
NOMESCO Finland
Other transduodenal endoscopic operation on bile duct or ampulla of Vater
16.7
7.3
11
7
Z01.8
ICD-10 Finland
Other specified special examinations
2.7
7.3
49
223
K29.5
ICD-10 Finland
Chronic gastritis, unspecified
10.8
7.2
13
13
L01XX05
ATC
hydroxycarbamide; oral
14.6
7.0
11
8
D50.0
ICD-10 Finland
Iron deficiency anaemia secondary to blood loss (chronic)
8.9
7.0
14
17
C07AG02
ATC
carvedilol; oral
4.4
6.8
18
45
120
Kela drug reimbursment
Hypogammaglobulinaemia
41.9
6.8
8
*
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
8.4
6.8
14
18
K75.9
ICD-10 Finland
Inflammatory liver disease, unspecified
23.7
6.7
9
*
A46
ICD-10 Finland
Erysipelas
2.9
6.7
38
157
R59.0
ICD-10 Finland
Localized enlarged lymph nodes
6.7
6.7
16
26
A10AE04
ATC
insulin glargine; parenteral
3.2
6.6
28
98
K76.0
ICD-10 Finland
Fatty (change of) liver, not elsewhere classified
8.0
6.6
14
19
GD1AD
NOMESCO Finland
Thorax CT examination
3.9
6.5
20
56
I50.0
ICD-10 Finland
Congestive heart failure
3.9
6.5
20
56
JA3AT
NOMESCO Finland
Cathetrisation of abdominal cavity with ultrasound guidance
15.1
6.5
10
7
174
Kela drug reimbursment
Ruxolitinib
72.6
6.5
7
*
374
Kela drug reimbursment
Ruxolitinib
72.6
6.5
7
*
9950/3-C42.1
ICD-O-3
Polycythemia vera of bone marrow
72.6
6.5
7
*
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
72.6
6.5
7
*
L01EJ01
ATC
ruxolitinib; oral
72.6
6.5
7
*
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
7.6
6.4
14
20
D69.3
ICD-10 Finland
Idiopathic thrombocytopenic purpura
27.9
6.3
8
*
A07AA11
ATC
rifaximin; oral
+∞
6.3
6
*
D70.82
ICD-10 Finland
Drug-induced neutropenia
+∞
6.3
6
*
D83.0
ICD-10 Finland
Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function
+∞
6.3
6
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
7.7
6.1
13
18
A06AD11
ATC
lactulose; oral
2.8
6.0
33
134
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
70
109
10.55
47.49
4.5
2.6
0.18
0.22
g/l
2.32
65
101
37
21
22.54
46.92
4.7
4.0
852.14
4817.40
u/ml
—
7
5
38
30
16.24
40.63
1.8
2.2
—
—
—
0
0
35
35
12.48
32.11
3.9
1.9
2.64
4.05
g/l
3.24
35
35
36
38
11.89
31.84
2.3
3.6
1.77
2.08
ratio
0.13
22
19
77
195
6.62
31.73
4.3
2.4
21.96
23.84
%
0.45
72
183
29
26
13.37
28.37
1.7
1.2
—
—
—
0
0
42
63
8.65
28.30
3.0
1.7
0.79
1.51
g/l
5.38
30
55
85
316
4.56
20.60
3.5
2.1
3.40
2.83
mg/l
1.18
75
277
59
167
4.98
20.26
9.9
2.9
11.76
4.88
umol/l
2.84
52
145
141
821
6.53
17.75
25.4
9.5
4.36
4.16
e9/l
0.14
130
708
40
96
5.20
16.43
3.1
1.7
—
—
—
0
0
64
224
4.07
16.18
3.6
2.0
—
—
—
0
0
24
35
7.88
16.18
3.7
1.9
182.67
205.89
%
0.42
24
35
59
196
4.16
16.02
2.1
1.7
1253.33
1203.06
nmol/l
0.14
47
161
27
26
12.22
14.92
1.9
1.2
148.60
169.29
au/ml
—
5
7
19
7
30.45
14.65
3.8
2.6
1460.21
708.57
u/ml
—
19
7
119
669
3.93
14.12
16.2
7.7
1.19
1.21
mmol/l
1.88
105
593
26
26
11.69
14.10
1.5
1.2
—
—
—
0
0
25
23
12.63
14.10
1.6
1.2
272.50
175.36
u/ml
0.53
12
14
24
41
6.70
13.98
3.3
1.8
—
—
—
0
0
24
41
6.70
13.98
3.4
1.8
—
—
—
0
0
49
168
3.75
12.38
2.8
1.8
—
—
—
0
0
18
10
20.04
12.37
2.6
2.0
—
—
—
0
0
89
447
3.20
12.05
5.7
2.8
57.30
72.91
u/l
0.51
83
417
25
55
5.19
11.15
2.8
3.2
—
—
—
0
0
21
40
5.88
10.91
2.2
1.7
—
—
—
0
0
27
65
4.78
10.84
2.7
3.1
14.06
7.44
iu/ml
—
5
15
45
160
3.51
10.62
3.1
1.9
—
—
—
0
0
22
45
5.50
10.61
1.4
1.3
—
—
—
0
0
18
16
12.49
10.35
1.3
1.1
—
—
—
0
0
22
47
5.26
10.11
2.3
1.9
1.08
1.16
g/l
0.61
22
47
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
19
37
5.68
9.62
5.4
2.5
0.33
0.30
iu/ml
0.13
11
20
20
41
5.42
9.59
2.0
1.2
—
—
—
0
0
29
83
4.04
9.30
5.7
3.2
1.46
1.47
mmol/l
0.01
19
56
66
327
2.72
8.48
6.7
2.3
—
—
—
0
0
22
55
4.47
8.38
2.6
1.8
2.05
1.36
ug/l
0.19
22
49
13
9
15.56
8.36
1.5
1.7
3.94
4.60
mg/l
—
13
9
20
33
6.76
8.16
1.9
1.6
—
—
—
0
0
11
5
23.43
8.13
1.3
3.0
—
—
—
0
0
11
5
23.43
8.13
1.3
3.0
—
—
—
0
0
17
24
7.78
7.71
3.4
1.8
—
—
—
0
0
19
32
6.58
7.66
3.1
1.5
—
—
—
0
0
95
583
2.52
7.61
3.1
2.0
101.58
95.66
pmol/l
0.43
61
298
103
658
2.55
7.55
7.4
2.9
—
—
estimate
—
0
0
12
9
14.27
7.51
1.6
1.2
—
—
—
0
0
14
15
10.09
7.45
4.9
1.3
33.00
34.00
pg
0.37
14
15
13
14
9.98
6.93
1.1
1.1
—
—
—
0
0
93
582
2.40
6.91
3.9
2.4
70.56
76.63
nmol/l
1.18
88
528
14
19
7.95
6.57
1.8
1.5
—
—
—
0
0
60
315
2.44
6.55
3.0
1.6
1.62
1.00
mg/l
0.89
47
248
36
147
2.86
6.52
7.2
3.5
1.71
1.88
mmol/l
0.13
31
123
10
7
15.11
6.48
1.1
1.0
—
—
—
0
0
17
32
5.81
6.36
2.2
1.9
—
—
—
0
0
39
169
2.72
6.30
10.4
10.4
0.98
1.25
mmol/l
0.15
34
144
16
39
4.44
6.25
1.2
1.3
—
—
—
0
0
12
14
9.15
6.17
1.4
1.3
—
—
—
0
0
24
80
3.35
6.10
10.8
14.4
14.45
15.87
%
1.96
24
80
16
30
5.80
6.03
2.3
1.9
—
—
—
0
0
16
32
5.43
5.74
1.3
1.4
—
—
—
0
0
12
17
7.53
5.55
1.9
1.5
—
—
—
0
0
12
17
7.53
5.55
1.6
1.9
—
—
—
0
0
22
75
3.24
5.39
1.3
1.4
—
—
—
0
0
9
8
11.82
5.36
2.3
1.4
—
—
—
0
0
9
8
11.82
5.36
2.3
1.4
—
—
—
0
0
23
82
3.10
5.24
13.8
8.3
24.27
24.94
mmol/l
0.32
23
82
5
0
+∞
5.23
1.0
0.0
—
—
—
0
0
14
27
5.57
5.22
1.6
1.4
—
—
—
0
0
14
27
5.57
5.22
1.6
1.4
—
—
—
0
0
39
185
2.46
5.18
3.2
2.0
1.64
1.50
%
0.64
32
164
9
9
10.50
5.09
2.2
1.9
24.00
11.22
u/l
—
9
9
67
403
2.13
5.06
5.4
3.1
0.25
0.46
e6/l
1.05
52
288
15
42
3.83
4.89
3.6
1.4
—
—
—
0
0
8
7
11.93
4.84
4.9
2.4
—
—
—
0
0
8
7
11.93
4.84
4.9
2.4
—
—
—
0
0
8
7
11.93
4.84
4.9
2.4
—
—
—
0
0
8
7
11.93
4.84
4.9
2.4
—
—
—
0
0
16
48
3.59
4.74
2.6
1.6
—
—
—
0
0
11
18
6.47
4.69
4.2
1.9
—
—
—
0
0
32
145
2.50
4.66
11.7
11.6
111.44
122.01
g/l
2.01
32
145
21
76
3.03
4.66
2.1
1.4
0.25
0.33
mg/l
—
10
35
7
5
14.54
4.62
4.3
2.2
0.64
0.61
mmol/l
—
7
5
10
15
7.03
4.54
4.1
1.9
—
—
—
0
0
10
15
7.03
4.54
4.1
1.9
—
—
—
0
0
10
15
7.03
4.54
4.1
1.9
—
—
—
0
0
32
147
2.47
4.52
2.6
5.1
2.69
35.07
ug/l
0.61
27
126
11
20
5.82
4.37
4.2
1.8
—
—
—
0
0
16
51
3.37
4.34
4.6
2.1
—
—
—
0
0
8
9
9.27
4.33
2.8
1.8
—
—
—
0
0
8
10
8.34
4.11
2.1
1.7
—
—
—
0
0
7
7
10.38
4.05
2.3
1.7
—
—
—
0
0
7
7
10.38
4.05
2.7
1.3
—
—
—
0
0
7
7
10.38
4.05
2.7
1.3
—
—
—
0
0
7
7
10.38
4.05
2.3
1.7
—
—
—
0
0
55
330
2.01
4.02
1.4
1.3
0.89
1.20
u/ml
0.31
15
102
19
73
2.82
3.80
2.8
1.5
—
—
—
0
0
37
199
2.11
3.59
13.6
6.8
103.30
104.10
mmol/l
0.45
37
199
7
9
8.06
3.59
2.4
1.6
—
—
—
0
0
6
6
10.32
3.52
5.8
2.3
—
—
—
0
0
6
6
10.32
3.52
5.8
2.3
—
—
—
0
0
6
6
10.32
3.52
5.8
2.3
—
—
—
0
0
40
225
2.03
3.45
3.9
2.9
1.89
1.66
e6/l
0.09
18
113
21
91
2.50
3.34
4.8
2.5
2.20
1.41
%
0.86
21
91
9
19
4.95
3.29
1.1
1.1
—
—
—
0
0
7
11
6.59
3.22
1.0
1.0
—
—
—
0
0
7
11
6.59
3.22
1.0
1.1
—
—
—
0
0
26
128
2.23
3.13
5.3
3.5
—
—
—
0
0
24
115
2.28
3.07
2.7
3.0
48.91
67.90
ml/min/173m2
1.03
11
49
14
51
2.91
3.07
3.1
1.8
—
—
—
0
0
7
12
6.04
3.05
1.0
1.1
—
—
—
0
0
98
753
1.76
3.05
5.7
3.6
88.72
0.00
estimate
0.79
29
168
5
5
10.26
3.00
1.0
1.0
—
—
—
0
0
76
547
1.73
2.95
7.7
3.8
27.54
36.15
ng/l
0.55
61
385
8
18
4.62
2.83
5.0
1.4
—
—
—
0
0
8
18
4.62
2.83
5.0
1.4
—
—
—
0
0
96
744
1.71
2.80
5.8
3.6
0.00
0.00
estimate
-0.00
27
165
97
756
1.71
2.75
5.7
3.7
0.00
0.00
estimate
-0.00
25
151
8
19
4.37
2.71
5.0
1.4
—
—
—
0
0
8
19
4.37
2.71
5.0
1.4
—
—
—
0
0
8
19
4.37
2.71
5.0
1.4
—
—
—
0
0
8
19
4.37
2.71
5.0
1.4
—
—
—
0
0
40
247
1.82
2.58
1.4
1.3
37.35
4.60
u/ml
—
10
100
40
248
1.81
2.54
3.7
2.7
0.66
0.95
e6/l
0.69
19
135
65
463
1.67
2.54
5.7
4.2
33.85
11.48
mg/mmol
0.85
44
309
19
90
2.26
2.50
1.2
1.2
26.89
138.63
u/ml
—
8
32
6
13
4.75
2.29
1.0
1.2
—
—
—
0
0
18
87
2.20
2.27
4.7
2.5
0.70
0.61
%
0.65
18
87
42
276
1.70
2.17
1.5
1.3
124.81
34.24
iu/ml
0.54
16
88
6
14
4.41
2.17
1.3
1.3
—
—
—
0
0
10
37
2.81
2.11
2.7
1.5
—
—
—
0
0
9
31
3.01
2.11
1.6
1.2
—
—
—
0
0
7
20
3.61
2.08
1.1
1.4
—
—
—
0
0
59
428
1.60
2.07
3.4
2.0
103.59
225.35
u/l
1.96
59
410
6
15
4.11
2.06
1.3
1.3
—
—
—
0
0
6
15
4.11
2.06
1.3
1.3
—
—
—
0
0
6
15
4.11
2.06
1.2
1.2
—
—
—
0
0
58
421
1.59
2.02
6.5
3.6
3.13
0.00
estimate
0.48
24
151
7
21
3.43
1.99
1.1
1.2
—
—
—
0
0
6
16
3.85
1.95
1.0
1.3
—
—
—
0
0
39
259
1.67
1.93
5.6
3.8
584.23
489.35
ng/l
0.06
33
203
120
1034
1.62
1.93
5.0
4.2
14.68
14.86
pmol/l
0.41
113
956
6
17
3.62
1.85
1.3
1.2
—
—
—
0
0
6
17
3.62
1.85
1.3
1.2
—
—
—
0
0
5
12
4.26
1.83
2.6
1.0
—
—
—
0
0
19
103
1.96
1.81
3.2
2.3
17.28
9.39
ug/l
0.35
13
92
5
13
3.93
1.73
2.4
1.7
—
—
—
0
0
5
13
3.93
1.73
2.6
1.1
—
—
—
0
0
8
31
2.66
1.68
2.4
1.1
—
—
—
0
0
6
20
3.07
1.59
2.3
3.7
—
—
—
0
0
149
1381
1.98
1.58
54.9
15.5
23.18
24.38
mg/l
0.21
144
1127
5
15
3.40
1.53
2.0
1.4
—
—
—
0
0
55
420
1.47
1.46
5.2
3.1
10.87
0.01
estimate
0.48
23
128
6
22
2.79
1.45
11.3
3.4
13.93
9.36
pmol/l
—
6
22
45
332
1.49
1.41
5.2
3.5
1.02
1.02
kg/l
0.61
32
217
9
41
2.26
1.39
1.3
1.4
—
—
—
0
0
70
569
1.41
1.30
6.0
3.5
0.00
0.00
estimate
-0.00
25
134
5
18
2.83
1.29
2.6
1.3
—
—
—
0
0
5
18
2.83
1.29
4.4
3.4
3.42
3.09
nmol/l
—
5
18
142
1318
1.63
1.22
46.1
15.0
79.71
83.04
ml/min/173m2
0.84
134
1227
11
193
0.54
1.17
1.6
1.6
—
—
—
0
0
127
1356
0.71
0.97
6.1
4.9
1.17
1.43
mmol/l
11.40
120
1271
122
1303
0.74
0.83
6.0
4.2
1.44
1.30
mmol/l
1.21
114
1217
131
1381
0.73
0.77
6.6
5.7
2.28
2.70
mmol/l
6.45
125
1294
125
1163
1.33
0.76
65.1
19.2
15.12
13.54
%
10.12
125
1156
129
1362
0.74
0.75
6.2
5.0
4.03
4.60
mmol/l
8.87
123
1283
7
42
1.70
0.69
1.7
1.2
—
—
—
0
0
7
42
1.70
0.69
1.7
1.2
—
—
—
0
0
5
27
1.88
0.69
2.0
1.3
—
—
—
0
0
136
1289
1.34
0.66
9.3
6.3
39.37
39.44
mmol/mol
0.02
126
1231
17
121
1.45
0.65
2.8
2.7
0.07
0.78
e6/l
0.48
17
115
5
30
1.69
0.62
1.8
1.2
0.93
0.88
nmol/l
—
5
24
133
1265
1.29
0.56
6.3
5.0
2.10
1.93
mu/l
0.71
125
1172
94
869
1.19
0.49
4.3
3.1
—
—
—
0
0
7
48
1.48
0.47
2.4
1.7
—
—
—
0
0
37
426
0.83
0.41
5.2
4.4
20.28
21.02
%
0.09
16
204
20
164
1.25
0.34
5.2
4.8
29.79
31.91
%
0.39
14
106
30
263
1.17
0.28
2.1
1.6
—
—
—
0
0
9
74
1.23
0.25
1.7
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
36.00
—
0
5
0
13
0.00
0.21
0.0
1.2
—
169.03
—
0
13
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
6
49
1.23
0.20
3.0
1.1
0.69
0.86
g/l
—
6
49
15
128
1.19
0.19
1.4
1.4
—
—
—
0
0
29
319
0.89
0.18
3.1
3.0
0.72
0.74
ug/l
0.06
20
206
8
70
1.15
0.16
1.4
1.7
—
—
—
0
0
14
149
0.93
0.03
12.6
7.8
—
—
—
0
0
133
1321
1.04
0.02
7.1
4.9
6.46
5.95
mmol/l
2.08
125
1228
16
153
1.05
0.01
1.7
1.9
—
—
—
0
0
17
166
1.03
0.00
1.9
2.0
—
—
—
0
0
15
153
0.98
0.00
2.5
2.4
11.25
13.94
nmol/l
0.78
15
144
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
24.57
—
0
7
7
77
0.91
-0.00
1.0
1.0
—
—
—
0
0
8
80
1.00
-0.00
2.0
1.9
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
0.23
—
0
6
Mortality – FinRegistry
↥Association
Association between endpoint D3_HYPERSPLENISM and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_HYPERSPLENISM | 6.062 [3.72, 9.87] | < 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.274 |
During the follow-up period (1.1.1998 — 31.12.2019), 136 out of 361 females with D3_HYPERSPLENISM died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_HYPERSPLENISM | 4.648 [3.31, 6.52] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 174 out of 469 males with D3_HYPERSPLENISM died.
Mortality risk
Mortality risk for people of age
years, who have D3_HYPERSPLENISM.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.658% | 0.829% |
| 5 | 3.469% | 5.303% |
| 10 | 8.399% | 13.102% |
| 15 | 16.608% | 22.798% |
| 20 | 27.309% | 36.245% |
Relationships between endpoints
↥Index endpoint: D3_HYPERSPLENISM – Hypersplenism
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data